Talphera, Inc. (NASDAQ:TLPH) Sees Significant Drop in Short Interest

Talphera, Inc. (NASDAQ:TLPH) saw a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 88,200 shares, a decline of 35.5% from the July 31st total of 136,700 shares. Based on an average trading volume of 52,200 shares, the short-interest ratio is presently 1.7 days. Approximately 0.5% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TLPH. Maxim Group began coverage on Talphera in a report on Monday, May 6th. They set a “buy” rating and a $3.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Talphera in a report on Friday, August 16th.

Talphera Price Performance

Shares of NASDAQ:TLPH opened at $0.97 on Wednesday. The stock has a market cap of $16.48 million, a price-to-earnings ratio of -1.09 and a beta of 0.33. Talphera has a 12 month low of $0.43 and a 12 month high of $1.61. The stock’s 50 day moving average price is $0.91 and its 200 day moving average price is $1.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Talphera stock. Turtle Creek Wealth Advisors LLC purchased a new stake in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned approximately 0.42% of Talphera as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.